MetrioPharm veröffentlicht Studiendaten, die die Wirkung einer Host-Directed Therapy in COVID-19 zeigen
31. Januar 2024 05:00 ET | AKAMPION
Ergebnisse stammen aus der klinischen Studie CT-05 an 131 hospitalisierten Patienten mit COVID-19Die Daten zeigen, dass MetrioPharms Leitsubstanz MP1032 eine mit Remdesivir vergleichbare Wirksamkeit...
MetrioPharm Publishes First Trial Data Showing Effects of Host-Directed Therapy in COVID-19
31. Januar 2024 05:00 ET | AKAMPION
Results of clinical trial CT-05 in 131 hospitalized patients with COVID-19Trial data demonstrate that MetrioPharm´s lead compound MP1032 has comparable efficacy to remdesivir with several additional...
Elevar Logo for Common Use.png
Elevar Therapeutics Announces Publication of Phase 3 CARES 310 Study Results in The Lancet
24. Juli 2023 21:39 ET | Elevar Therapeutics
FORT LEE, N.J., July 24, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating...
The Lancet Commissio
The Lancet Commission Formally Recognizes the Term ‘Profound Autism’
07. Dezember 2021 09:00 ET | Autism Science Foundation
New York, Dec. 07, 2021 (GLOBE NEWSWIRE) -- The Autism Science Foundation (ASF), a nonprofit organization dedicated to supporting and funding innovative autism research, today calls attention to the...
HearingLife-logo-cmyk FOR PRINT.jpg
New Report by The Lancet Commission Finds Hearing Loss in Midlife To Be the Largest Modifiable Risk Factor for Dementia
20. August 2020 09:05 ET | HearingLife Canada
TORONTO, Aug. 20, 2020 (GLOBE NEWSWIRE) -- HearingLife, Canada’s largest group of hearing centres, announced today that a new report in The Lancet, one of the world’s most-prestigious medical...